Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Coatings functionalize surfaces or protect them from processes such as corrosion, abrasion, and weathering, and may provide an aesthetic appearance—automotive coatings and non-stick frying pans are good examples. Contact lenses, implants, LEDs, or photovoltaic cells require extremely thin coatings. In the journal Angewandte Chemie, the teams led by Gero Decher at the Institut Charles Sadron in Strasbourg (France) have now introduced a new process for the production of ultrathin coatings that is especially simple, versatile, and suitable for large-scale processes.
Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also represents another step towards new organ replacement therapies.
Researchers have started the world’s first clinical trial of stem cells to treat stroke victims in Glasgow. The trial is undertaken by ReNeuron, a Guildford-based biotech company and started this weekend with an elderly man receiving an injection of 2 million stem cells into his brain. It received final approval to go ahead this year.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.
Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into an agreement to produce a high content screening tool for its biotech R&D subsidiary, Shrink Chips LLC.
Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.
Balaji Sitharaman, Ph.D., Assistant Professor of Biomedical Engineering at Stony Brook University, is a 2010 recipient of the National Institutes of Health (NIH) Director's New Innovator Award.
Danny Bluestein, Ph.D., Professor of Biomedical Engineering at Stony Brook University, has been awarded a five-year, $7.5 million grant by the National Institutes of Health. The award marks the first time a Stony Brook professor has received a Phase II Quantum Grant, given by The National Institute of Biomedical Imaging and Bioengineering (NIBIB), a division of the NIH, to make a profound improvement or quantum leap forward—in health care.
In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.
NovaSterilis, Lansing NY, and Dr. CC Chu were awarded a grant from the Metropolitan Development Association (MDA) to explore the feasibility of utilizing NovaSterilis supercritical co2 sterilization for a variety of absorbable biomaterials from both commercial and experimental sources.
Many scientists aspire to take control over the stem cell differentiation process, so that we can grow organs and implants perfectly matched to each patient in the future. Now research in the Journal of Tissue Engineering, published by SAGE-Hindawi, explains how engineering the topography on which stem cells grow, and the mechanical forces working on them, can be as powerful an agent for change as their chemical environment.
A research team, co-headed by Dr. Woo Lee and Dr. Hongjun Wang of Stevens Institute of Technology, has published a paper describing a new method that generates three-dimensional tissue models for studying bacterial infection of orthopedic implants. Dr. Joung-Hyun Lee of Stevens, and Dr. Jeffrey Kaplan of the New Jersey Dental School, are co-authors of the research.
The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article, which is published online ahead of print, is available free online at www.liebertpub.com/hum
ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.
A new approach to anchor teeth back in the jaw using stem cells has been developed and successfully tested in the laboratory for the first time by researchers at the University of Illinois at Chicago.
Biomerix Corporation, a medical technologies company developing and manufacturing innovative regenerative medicine biomaterials, and Synthecon, a leading biotechnology company specializing in the design and manufacturing of rotating cell culture systems, today announced a strategic distribution agreement for three-dimensional cell culture scaffolds developed using Biomerix Corporation's unique biomaterial technology.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign, have been filed.
Fat-derived stem cells can be safely used to aid reconstruction of breast tissue after mastectomy as long as there is no evidence of active cancer, according to researchers at the University of Pittsburgh School of Medicine.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.